Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	**Regis Healthcare Ltd**
ABN	**11 125 203 054**

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Linda Jane Mellors
Date of last notice	3 October 2025

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	**<u>Direct</u>** Vesting and conversion into ordinary shares of Rights granted to Dr Mellors by the Company pursuant to the FY2022 Variable Reward and Retention Plan (**VRRP**) and the FY2023 Long Term incentive (**LTI**) plan. Rights granted under each plan were approved at the Annual General Meeting held on 25 October 2022. **<u>Indirect</u>** Grant of Rights to Dr Mellors by the Company pursuant to the FY25 STI Plan (**FY25 STI**). Hazelwood Gates Pty Ltd (Davies and Mellors Family Trust) has been nominated as the recipient by Dr Mellors.
Date of change	10 October 2025 and 13 October 2025
No. of securities held prior to change	284,270 Ordinary Shares 924,710 Rights (unquoted)
Class	Ordinary Shares Rights (unquoted)

+ See chapter 19 for defined terms.

Number acquired	419,690 Ordinary Shares 13,756 Rights (unquoted)
Number disposed	419,690 Rights (unquoted)
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	No cash consideration is payable. **VRRP and LTI** Vesting of Rights issued to the Managing Director under the VRRP and LTI and conversion to Ordinary shares. No amount is payable on vesting or conversion. **FY25 STI** Rights issued under the FY25 STI plan No amount is payable on grant of Rights.
No. of securities held after change	703,960 Ordinary Shares 518,776 Rights (unquoted)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	**VRRP and LTI** Vesting of Rights granted to Dr Mellors by the Company pursuant to the 2022 VRRP and the 2023 LTI Plan, both approved at the Annual General Meeting held on 25 October 2022 (subject to continued employment condition). **FY25 STI** Grant of Rights to Dr Mellors by the Company pursuant to the FY25 STI (subject to continued employment condition).

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder **(if issued securities)**	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	

Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.